From Yahoo Finance: 2025-05-11 17:26:00

President Trump’s healthcare-focused executive order aims to revamp laws allowing Medicare to negotiate prescription drug prices, a change long lobbied for by pharmaceutical companies. The order directs collaboration between the health department and Congress to make the change, although legislation is required for implementation. Drug makers have been striving to delay price negotiation eligibility timelines for small-molecule drugs by four years, along with a 13-year wait for more complex biotech drugs. Trump’s order also targets slashing healthcare costs and follows a national security report on the pharma industry, possibly leading to sector-specific tariffs. Medicare’s negotiations have stirred controversy, particularly with drug makers concerned about innovation suppression. The law currently permits price negotiations for drugs with no competition, including complex biotech medications after 13 years on the market, or 9 years if in pill form. The Biden administration achieved price cuts as deep as 79% for the top ten most expensive drugs, with the Trump administration set to negotiate for 15 additional medications, including cancer and diabetes treatments. Soleno Therapeutics, Inc. (NASDAQ: SLNO) is a clinical-stage biopharmaceutical company focusing on developing novel therapeutics for rare diseases. Their lead candidate, Diazoxide Choline Controlled-Release (DCCR), treats Prader-Willi Syndrome. VYKAT XR extended-release tablets for Prader-Willi syndrome are now available in the U.S., with a support program named Soleno ONE to aid healthcare providers and patients. H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on SLNO with a price target of $100.00. Despite SLNO ranking 3rd on the list of best healthcare stocks, there are AI stocks showing greater promise for higher returns within a shorter period. Check out Insider Monkey’s report for an AI stock with significant potential.



Read more at Yahoo Finance: Is Soleno Therapeutics (SLNO) the Best Performing Healthcare Stock to Buy Now?